A new tool powered by artificial intelligence (AI) to automatically analyse optical coherence tomography (OCT) scans has obtained CE certification and has been launched in Europe. An application has been made for United States Food and Drug Administration clearance.
Altris AI was created by a team of retina experts led by the Maria Znamenska, who has a PhD in ophthalmology. Dr Znamenska is also the owner of an eye clinic in Kyiv, Ukraine, and all the specialists of Altris AI are practising ophthalmologists.
The first Altris AI prototype for the detection of two pathological conditions and a normal retina was developed in November 2017. Five months later, in April 2018 Altris was among the winners of the Global New Venture Challenge, a global startup competition of the University of Chicago Booth School of Business.
According to Altris, the platform is attracting widespread interest among the UK optometry centres where over 70 Altris AI accounts are currently active. Altris Education OCT, an education tool, is used by over 15,000 ophthalmologists and optometrists.
Altris AI has two modules: AI Severity Detection and AI Segmentation/Classification.
AI Severity Detection differentiates between low, medium, and high-severity OCT scans.
AI Segmentation/Classification differentiates between 74 pathologies and pathological signs, including widespread pathologies such as diabetic retinopathy, glaucoma, or wet age-related macular degeneration as well as rare pathologies, such as vitelliform dystrophy.
A free trial is available.
